Synairgen Management

Management criteria checks 4/4

Synairgen's CEO is Richard Marsden, appointed in Sep 2009, has a tenure of 14.75 years. total yearly compensation is £328.00K, comprised of 94.5% salary and 5.5% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth €49.35K. The average tenure of the management team and the board of directors is 3.4 years and 16.5 years respectively.

Key information

Richard Marsden

Chief executive officer

UK£328.0k

Total compensation

CEO salary percentage	94.5%
CEO tenure	14.8yrs
CEO ownership	0.5%
Management average tenure	3.4yrs
Board average tenure	16.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Richard Marsden's remuneration changed compared to Synairgen's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	UK£328k	UK£310k	-UK£8m
Sep 30 2023	n/a	n/a	-UK£9m
Jun 30 2023	n/a	n/a	-UK£10m
Mar 31 2023	n/a	n/a	-UK£14m
Dec 31 2022	UK£328k	UK£310k	-UK£18m
Sep 30 2022	n/a	n/a	-UK£23m
Jun 30 2022	n/a	n/a	-UK£28m
Mar 31 2022	n/a	n/a	-UK£38m
Dec 31 2021	UK£1m	UK£256k	-UK£49m
Sep 30 2021	n/a	n/a	-UK£46m
Jun 30 2021	n/a	n/a	-UK£43m
Mar 31 2021	n/a	n/a	-UK£28m
Dec 31 2020	UK£415k	UK£194k	-UK£14m
Sep 30 2020	n/a	n/a	-UK£10m
Jun 30 2020	n/a	n/a	-UK£6m
Mar 31 2020	n/a	n/a	-UK£5m
Dec 31 2019	UK£289k	UK£190k	-UK£4m
Sep 30 2019	n/a	n/a	-UK£4m
Jun 30 2019	n/a	n/a	-UK£4m
Mar 31 2019	n/a	n/a	-UK£3m
Dec 31 2018	UK£205k	UK£186k	-UK£3m
Sep 30 2018	n/a	n/a	-UK£898k
Jun 30 2018	n/a	n/a	UK£2m
Mar 31 2018	n/a	n/a	UK£2m
Dec 31 2017	UK£336k	UK£182k	UK£2m

Compensation vs Market: Richard's total compensation ($USD414.63K) is about average for companies of similar size in the German market ($USD433.43K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Marsden (57 yo)

14.8yrs

Tenure

UK£328,000

Compensation

Mr. Richard Marsden has been Chief Executive Officer of Synairgen Research Ltd since September 2009. Mr. Marsden has been Managing Director and Executive Director at Synairgen since June 2004 has been its...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Marsden	CEO, MD & Executive Director	14.8yrs	UK£328.00k	0.49% € 49.4k
Stephen Holgate	Co-Founder	no data	UK£40.00k	0.45% € 45.2k
Joseph Colliver	CFO & Executive Director	less than a year	UK£197.41k	no data
Phillip Monk	Chairman of Scientific Advisory Board	14.8yrs	UK£241.00k	0.21% € 21.0k
Donna Davies	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Gareth Walters	Chief Regulatory Officer	2.7yrs	no data	no data
Jody Brookes	Senior VP & Head of Clinical Operations	12.5yrs	no data	no data
Richard Francis	Senior VP and Head of CMC & Quality	2.8yrs	no data	no data
Victoria Tear	Head of Laboratory	5.2yrs	no data	no data
Marcin Mankowski	Chief Medical Officer	less than a year	no data	no data
Simon Holden	Company Secretary	3.4yrs	no data	no data

3.4yrs

Average Tenure

56yo

Average Age

Experienced Management: OMY's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Marsden	CEO, MD & Executive Director	20yrs	UK£328.00k	0.49% € 49.4k
Stephen Holgate	Co-Founder	21yrs	UK£40.00k	0.45% € 45.2k
Joseph Colliver	CFO & Executive Director	less than a year	UK£197.41k	no data
Phillip Monk	Chairman of Scientific Advisory Board	14.8yrs	UK£241.00k	0.21% € 21.0k
Donna Davies	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Simon James Shaw	Non-Executive Chairman	21yrs	UK£84.00k	0.76% € 75.9k
David Campbell	Non-Executive Director & Member of Scientific Advisory Board	18.2yrs	UK£40.00k	0.16% € 16.4k
Felicity Gabbay	Member of Scientific Advisory Board & Independent Non-Executive Director	1.8yrs	UK£45.00k	no data
Amanda Radford	Independent Non-Executive Director	1.6yrs	UK£45.00k	no data

16.5yrs

Average Tenure

58yo

Average Age

Experienced Board: OMY's board of directors are seasoned and experienced ( 16.5 years average tenure).

Synairgen Management

Management criteria checks 4/4

Key information

Recent management updates

Synairgen plc, Annual General Meeting, Oct 10, 2024

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc Announces Executive Changes

Synairgen plc Announces Board Changes

Recent updates

Synairgen plc, Annual General Meeting, Oct 10, 2024

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc Announces Executive Changes

Synairgen plc Announces Board Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc, Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Less than half of directors are independent

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Less than half of directors are independent

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Less than half of directors are independent

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

Less than half of directors are independent

No independent directors

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: €2.14

New 90-day high: €2.08

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - €2.52

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age